Concurrent Investment Advisors LLC Purchases New Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Concurrent Investment Advisors LLC purchased a new stake in Humacyte, Inc. (NASDAQ:HUMA) during the third quarter, according to its most recent disclosure with the SEC. The firm purchased 13,800 shares of the company’s stock, valued at approximately $75,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HUMA. Endowment Wealth Management Inc. lifted its stake in Humacyte by 3.1% in the 2nd quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock worth $482,000 after purchasing an additional 3,000 shares in the last quarter. nVerses Capital LLC purchased a new position in Humacyte in the 2nd quarter worth approximately $28,000. Private Advisor Group LLC lifted its stake in Humacyte by 1.8% in the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock worth $2,030,000 after purchasing an additional 6,510 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Humacyte by 32.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock worth $168,000 after purchasing an additional 8,557 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Humacyte by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock worth $125,000 after purchasing an additional 8,965 shares in the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HUMA has been the topic of several analyst reports. TD Cowen reaffirmed a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. HC Wainwright lifted their price target on shares of Humacyte from $6.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. BTIG Research reaffirmed a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. Finally, Benchmark reaffirmed a “buy” rating and set a $15.00 price target on shares of Humacyte in a research report on Thursday, October 10th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $11.00.

Insiders Place Their Bets

In other Humacyte news, Director Kathleen Sebelius sold 5,182 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the transaction, the director now owns 40,276 shares in the company, valued at $217,490.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Brady W. Dougan sold 252,676 shares of Humacyte stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the completion of the sale, the director now directly owns 4,306,464 shares of the company’s stock, valued at approximately $28,896,373.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total transaction of $27,982.80. Following the sale, the director now directly owns 40,276 shares of the company’s stock, valued at approximately $217,490.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,084,153 shares of company stock worth $6,869,996 over the last 90 days. Corporate insiders own 11.20% of the company’s stock.

Humacyte Stock Down 2.9 %

Humacyte stock opened at $5.36 on Wednesday. Humacyte, Inc. has a fifty-two week low of $2.21 and a fifty-two week high of $9.97. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41. The firm has a 50 day moving average price of $5.45 and a 200 day moving average price of $6.17. The company has a market capitalization of $639.72 million, a PE ratio of -4.12 and a beta of 1.47.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Research analysts expect that Humacyte, Inc. will post -1.18 earnings per share for the current year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.